Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02468245|
Recruitment Status : Recruiting
First Posted : June 10, 2015
Last Update Posted : July 10, 2019
|Condition or disease||Intervention/treatment||Phase|
|Antineoplastic Agents||Behavioral: weekly telephone follow up Behavioral: usual care||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||June 2020|
Active Comparator: Control Arm
This is a "usual care" group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit.
Behavioral: usual care
The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
Experimental: Intervention arm
Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
Behavioral: weekly telephone follow up
For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
- Oral chemotherapy compliance [ Time Frame: 4 weeks ]A 4 week pill count will be completed on all participants to measure drug compliance.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02468245
|Contact: jennifer victory, RNfirstname.lastname@example.org|
|United States, New York|
|Bassett Healthcare Network||Recruiting|
|Cooperstown, New York, United States, 13326|
|Contact: Jennifer Victory, RN 607-547-6965 email@example.com|
|Principal Investigator: Kelly Morris, RN|
|Principal Investigator:||kelly morris, RN||Bassett Healthcare|